<DOC>
	<DOC>NCT02859727</DOC>
	<brief_summary>This study is designed to provide long-term CDZ173 treatment, a selective PI3Kδ inhibitor, to the patients with genetically activated PI3Kδ, i.e., patients with APDS/PASLI that already participated to the CDZ173X2201 study. The study is open-label designed to establish the long-term safety, tolerability, efficay and pharmacokinetics of CDZ173 in the target population.</brief_summary>
	<brief_title>Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<criteria>Written informed consent must be obtained before any assessment is performed. Paients must have completed the study CCDZ173X2201, i.e., had the EOS visit of study CCDZ173X2201 Patients who are deemed by the Investigator to benefit from CDZ173 therapy. Patients or their legal representatives (for patients under the age of 18 years) must be able to communicate well with the Investigator, to understand and comply with the requirements of the study. Any medically significant disease or condition that is unrelated to APDS/PASLI Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>APDS; PASLI; PI3Kdelta; p110delta-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency; Activated PI3Kdelta Syndrome;</keyword>
</DOC>